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ABSTRACT
Objective Racecadotril is an antisecretory agent that
can prevent ﬂuid/electrolyte depletion from the bowel as
a result of acute diarrhoea without affecting intestinal
motility. An up-to-date systematic review is indicated to
summarise the evidence on racecadotril for the treatment
of acute diarrhoea in children.
Design A Cochrane format systematic review of
randomised controlled trials (RCTs). Data extraction and
assessment of methodological quality were performed
independently by two reviewers. Methodological quality
was assessed using the Cochrane risk of bias tool.
Patients Children with acute diarrhoea, as deﬁned by
the primary studies.
Interventions RCTs comparing racecadotril with
placebo or other interventions.
Main outcome measurs Duration of illness, stool
output/volume and adverse events.
Results Seven RCTs were included, ﬁve comparing
racecadotril with placebo or no intervention, one with
pectin/kaolin and one with loperamide. Moderate to
high risk of bias was present in all studies. There was no
signiﬁcant difference in efﬁcacy or adverse events
between racecadotril and loperamide. A meta-analysis of
three studies with 642 participants showed signiﬁcantly
shorter duration of symptoms with racecadotril compared
with placebo (mean difference −53.48 h, 95% CI
−65.64 to −41.33). A meta-analysis of ﬁve studies with
949 participants showed no signiﬁcant difference in
adverse events between racecadotril and placebo (risk
ratio 0.99, 95% CI 0.73 to 1.34).
Conclusions There is some evidence that racecadotril
is more effective than placebo or no intervention in
reducing the duration of illness and stool output in
children with acute diarrhoea. However, the overall
quality of the evidence is limited due to sparse data,
heterogeneity and risk of bias. Racecadotril appears to
be safe and well tolerated.
BACKGROUND
Acute diarrhoea, with or without vomiting, consti-
tutes approximately 14% of presentations to paedi-
atric A&E departments every year in the UK,1
leading to over 50 000 acute admissions annually
in England alone.2 Acute watery diarrhoea con-
tinues to cause signiﬁcant morbidity in infants and
young children both in developing3 and developed4
countries, despite advances in oral rehydration
therapy and newly developed vaccines. As a result,
this condition remains a substantial ﬁnancial
burden to the NHS at both secondary and tertiary
level care.2
Although diseases leading to an acute diarrhoeal
illness are often self-limiting, shortening of the
illness duration can have signiﬁcant beneﬁts with
regard to hydration and subsequent morbidity. Oral
rehydration therapy, although still underused in
some areas,5 has become the foundation during an
acute diarrhoeal illness although, increasingly,
μ-opioid receptor agonists have become more
popular in certain situations.6 Racecadotril is an
antisecretory agent with a different mechanism of
action from existing antidiarrhoeal agents. It func-
tions by selective inhibition of the enzyme neutral
endopeptidase (also known as enkephalinase), a cell
membrane peptidase enzyme found most com-
monly on the epithelium of the small intestine.7
The enzyme neutral endopeptidase degrades
endogenous enkephalins in the intestinal mucosa
which normally exhibit pro-absorptive and antise-
cretory properties. Racecadotril therefore aims to
promote these antisecretory properties by prolong-
ing the presence of the enkephalins through the
inhibition of neutral endopeptidase. Ultimately, the
hypersecretion of water and electrolytes is reduced
without affecting intestinal motility/transit.
The main aim of treatment with racecadotril is to
prevent ﬂuid/electrolyte depletion from the bowel
as a result of acute diarrhoea. The drug should be
used alongside oral rehydration solution (ORS) as
recommended by the National Institute of Health
and Care Excellence (NICE) clinical guideline
CG84 in children aged >3 months, as per licensing
regulations. The treatment should be started
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What is already known on this topic
▸ Oral rehydration solution (ORS) is the mainstay
of treatment for acute diarrhoea in children.
▸ Racecadotril is an antisecretory agent with a
different mechanism of action from existing
antidiarrhoeal agents that can be used with
ORS to prevent ﬂuid and electrolyte depletion.
▸ Previous reviews are limited by age and
signiﬁcant methodological ﬂaws.
What this study adds
▸ The evidence synthesised suggests that the
addition of racecadotril to ORS can reduce the
length of symptoms as well as the number and
volume of stools passed during the illness.
▸ The use of racecadotril appears self and well
tolerated in children with acute diarrhoea.
▸ The evidence base is generally of low quality
and at high risk of bias.
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following three episodes of watery diarrhoea in a 24 h period,
until two normal stools have been produced. The product
should be used for a maximum of 7 days.
The intervention with racecadotril aims to reduce symptoms
of acute diarrhoea within the ﬁrst 24 h of treatment by reducing
stool frequency without affecting intestinal motility. Side effects
of abdominal pain, bloating and rebound constipation, which
occur with other well-known antidiarrhoeal agents, would not
be expected with this treatment.
Racecadotril was ﬁrst licensed in France in 1992 but has only
been licensed and marketed since 2013 for use in children within
the UK. Although there have been previously published reviews
of the literature regarding racecadotril that included some
meta-analysis, there are some clear limitations to this work. A
review from 2007 is now signiﬁcantly out of date with just three
studies included.8 A review from 2011 has signiﬁcant methodo-
logical ﬂaws with one of the included studies not a randomised
controlled trial (RCT) and a further study written by one of the
review authors who would not provide more methodological
data when requested.9 Additionally, neither of these reviews
aligned themselves with the internationally recognised Cochrane
standard for evidence synthesis. An up-to-date systematic review
using the Cochrane Collaboration format is therefore indicated to
summarise the current evidence on the efﬁcacy and safety of race-
cadotril for the treatment of acute diarrhoea in children.
METHODS
The objectives of this review were to evaluate the efﬁcacy and
safety of racecadotril for the treatment of acute diarrhoea in chil-
dren. A full protocol for the study was completed by the authors
prior to commencement of the study and is available on request.
Criteria for considering studies for this review
RCTs were included in this systematic review. Participants were
aged 3 months to 18 years with a diagnosis of acute diarrhoea
(deﬁned as three or more episodes of watery diarrhoea in a 24 h
period within the last 72 h). Studies compared racecadotril with
another intervention or placebo, with all preparations and
dosing regimens considered. Studies could give ORS to both
groups, as this is the recommended administration method for
racecadotril. The primary outcome measure for the studies was
the total duration of diarrhoeal illness in days, as deﬁned by the
initial inclusion criteria. Secondary outcomes included: number
of diarrhoeal episodes occurring per day at 48 h following treat-
ment, duration of time taken for resolution of symptoms, stool
output in kg per day in ﬁrst 48 h after treatment, use of con-
comitant or alternative therapies such as other antidiarrhoeal
agents, need for hospital admission, duration of hospital stay if
admitted as inpatient and occurrence of any adverse events.
Search methods for identiﬁcation of studies
Electronic searches (search strategy not limited by language)
were completed of MEDLINE (1966 to 23 February 2015;
National Library of Medicine, Bethesda, USA), EMBASE (1974
to 23 February 2015; Elsevier Science, New York, USA),
Cochrane Central Register of Controlled Trials and Cochrane
Inﬂammatory Bowel Disease and Functional Bowel Disorder
Group Specialized Trials Register. The search strategy is shown
in online supplementary appendix 1.
Similar search strategies, modiﬁed appropriately and using the
same keywords, were used to search the other electronic data-
bases listed above. There is some evidence that data from
abstracts can be inconsistent with data in published articles.10
Therefore, relevant citations published in abstract form that met
the inclusion criteria were only considered if the author could
offer sufﬁcient data regarding risk of bias and outcomes.
The references of all identiﬁed studies were inspected for more
trials. Leaders in the ﬁeld were contacted to try to identify other
studies. Finally, the manufacturers of racecadotril were contacted
for additional data. Unpublished studies were considered if they
offered appropriate methodological and quality data.
Data collection and analysis
All identiﬁed abstracts and results from searches were reviewed
by the authors. If the reference appeared relevant, a full copy of
Table 1 Excluded papers with reasons
Excluded paper Reason
Alam et al13 Adult RCT
Alvarez Calatayud et al14 Not RCT
Cojocaru et al15 Not randomised trial (alternate patient entry)
Guarino et al16 Review article
Huighebaert et al 7 Review article
Lehert et al9 Review and meta-analysis
Mehta et al18 Not RCT
Pieścik-Lech et al19 Review article
Rao20 Not RCT
Rautenberg et al21 Not RCT
Tebruegge22 Review article discussing another trial
Tormo et al23 Review article
Savitha24 Abstract study, never published in full, author
contacted and responded but could not supply
further data to judge inclusion
Szajewska et al8 Previous systematic review
RCT, randomised controlled trial.
Figure 1 Flow diagram for search.
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Table 2 Characteristics of included studies and risk of bias
Study Year No Age
Racecaodotril
regimen1
Control
agent1 Context
Risk of bias
Randomisation
Allocation
Concealment Blinding
Incomplete
outcomes
Selective
reporting Other
Cézard et al25 2001 172 3 months–4 years 1.5 mg/kg
administered orally
3 times daily
Placebo Inpatient, 13
separate French
hospitals
Stated randomised
but not method
given
Not mentioned Double
blinded
Low risk All appropriate
outcome data
Involvement with
pharma not clear, many
recruited patients did not
meet inclusion
Gutiérrez-Castrellón
et al26
2010 280 1 month–2 years 1.5 mg/kg
administered orally
3 times daily
Placebo Inpatient,
Mexico
Computer generated Central
allocation
Double
blinded
Low risk All appropriate
outcome data
Authors confirm no drug
company involvement
Gutiérrez-Castrellón
et al 26
2010 184 1 month–2 years 1.5 mg/kg
administered orally
3 times daily
Placebo Outpatient,
Mexico
Computer generated Central
allocation
Double
blinded
Low risk All appropriate
outcome data
Authors confirm no drug
company involvement
Salazar Lindo et al27 2000 135 3–35 months 1.5 mg/kg
administered orally
3 times daily
Placebo Inpatient, Peru Stated randomised
but not method
given
Not mentioned Double
blinded
Low risk All appropriate
outcome data
Authors confirm no drug
company involvement
Santos et al28 2009 189 3–36 months 1.5 mg/kg
administered orally
3 times daily
Placebo Outpatient,
single centre,
Spain
Computer generated Not successfully
concealed
Open label One patient’s
details missing
All appropriate
outcome data
Authors confirm no drug
company involvement,
except in initial design
Melendez Garcia
et al29
2007 50 3–71 months Not specified Kaolin/pectin Outpatient,
Guatemala
Stated randomised
but not method
given
Not mentioned Unclear
how
blinded
Not complete No side effect
data
None apparent
Turck et al30 1999 102 2–10 years 1.5 mg/kg
administered orally
3 times daily
0.03 mg/kg
loperamide
Outpatient,
multiple French
centres
Stated randomised
but not method
given
Not mentioned Double
blinded
Low risk All appropriate
outcome data
None apparent
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the study was obtained. After reading the full texts, each author
independently assessed the eligibility of all trials identiﬁed based
on the inclusion criteria above. Disagreement among authors
was discussed and agreement reached by consensus. If the data
to judge inclusion were unclear, attempts were made to contact
the authors.
A data extraction form was developed and piloted to extract
information on relevant features and results of all primary and
secondary outcomes of included studies. The two reviewers sep-
arately extracted and recorded data on the predeﬁned checklist,
with disagreement discussed and consensus reached.
The risk of bias of selected trials was assessed independently
by the authors using the Cochrane risk of bias tool,11 with dis-
agreement once again resolved by reaching consensus. Study
authors were contacted for further information when insufﬁ-
cient information was offered to judge risk of bias or data were
missing for primary outcomes.
Analysis was completed using Revman (Review Manager 5.2,
V.5.2.9, The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, 2012). The primary outcome—
total duration of diarrhoeal illness—was assessed using the
mean difference (MD) with 95% CI. The secondary outcomes
were assessed by calculating the risk ratio (RR) and 95% CI or
the MD with 95% CI, as indicated. The authors of included
studies were again contacted to supply any missing data.
Heterogeneity among trial results was assessed by inspection
of graphical presentations and by calculating the χ2 test of het-
erogeneity (a p value of 0.10 was regarded as statistically signiﬁ-
cant). We also used the I2 statistic to quantity the effect of
heterogeneity.12 A random-effects model was used, with a sensi-
tivity analysis with the ﬁxed-effects model, to identify differ-
ences in results that would suggest heterogeneity.
RESULTS
Description of studies
The electronic database search identiﬁed 1178 studies that were
screened for inclusion. Of these, 21 studies were judged to be
potentially relevant and subjected to full text review (ﬁgure 1).
Experts were contacted, but no extra reports were received and
no further studies were identiﬁed from drug companies.
Fourteen reports were excluded for failing to meet the inclu-
sion criteria (table 1). One was an abstract with insufﬁcient data
to judge inclusion, one was an adult RCT, ﬁve were studies that
were not RCTs and seven were review articles or opinion pieces.
Of particular note, three of these 14 studies were included in a
previously published meta-analysis.9 One study was only pub-
lished in this existing meta-analysis and did not offer appropri-
ate information to judge inclusion.24 The author was contacted
but was not able to offer further information so the study was
excluded. Two further studies were not randomised14 15 (one
was published in Spanish and when translated was not random
and one used alternate assignment into each group, an inappro-
priate method of randomisation).
Six reports of seven studies satisﬁed the inclusion criteria and
were included in the review (table 2). Five studies compared
racecadotril with placebo. One of these reports described two
studies, an inpatient and an outpatient study.26 The author was
contacted and was able to offer sufﬁcient data to allow the
studies to be analysed separately. One study compared racecado-
tril with loperamide and one study compared racecadotril with
kaolin. The total number of participants in the seven studies
was 1112. All participants were children between 1 month and
10 years of age with acute diarrhoea.
Risk of bias of included studies
Three studies were rated as low risk for random sequence gener-
ation (selection bias) because these studies employed computer-
generated randomisation. The remaining studies described
themselves as randomised but, with no further details given or
available from authors, were rated as unclear risk of bias.
Two studies were rated as low risk of bias for allocation con-
cealment (selection bias). Four studies were rated as unclear risk
of bias for allocation concealment as the methods were not
clearly described in the manuscripts. One study described a
method that did not ensure allocation concealment and so was
rated as high risk of bias.29
Five studies were double-blinded and were judged to be at
low risk of bias for blinding of participants and personnel (per-
formance bias). One study described itself as blinded, but gave
no further details so was rated as unclear risk of bias. One study
was open-label and judged to be at high risk of bias for blinding
of participants and personnel.
Five studies reported full and appropriate data and satisfactor-
ily documented withdrawals and dropouts and were therefore
Figure 2 Forest plot of duration of diarrhoeal symptoms, racecadotril versus placebo.
Figure 3 Forest plot of stool output in the ﬁrst 48 h, racecadotril versus placebo.
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judged to be at low risk of bias for incomplete outcome data
(attrition bias) and six were judged as low risk for selective
reporting (reporting bias). Two studies did not record full data
for all patients and were judged high risk of bias for attrition
bias. One study did not offer outcome data regarding side
effects and so was judged at high risk for reporting bias.
Finally, all but one study were judged to be at low risk for
other sources of bias. This study had an afﬁliation with a
pharmaceutical company, but details of the extent of involve-
ment were unavailable and so it was judged to be at unclear risk
of bias. Details are summarised in table 2.
Racecadotril versus placebo
Efﬁcacy
Three studies with 642 participants presented data on the
primary outcome, duration of diarrhoeal symptoms.
Meta-analysis showed signiﬁcantly shorter duration of diar-
rhoeal symptoms in patients in the racecadotril group compared
with patients receiving placebo or no intervention (MD
−53.48 h, 95% CI −65.64 to −41.33, ﬁgure 2). A sensitivity
analysis with the ﬁxed-effects model did not change the result.
In the other studies the data were not reported in a manner that
allowed inclusion within this meta-analysis.
For secondary outcomes, studies reported differently based
on the setting of patients. Meta-analysis of two studies with 405
inpatient participants showed signiﬁcantly less stool output in
the ﬁrst 48 h of treatment in the racecadotril group compared
with placebo or no intervention (MD −150 g/kg, 95% CI −291
to −8.9, ﬁgure 3). This result showed signiﬁcant heterogeneity,
but was still signiﬁcant using a ﬁxed-effects model.
Meta-analysis of three studies with 422 outpatient participants
showed less stool output per day at 48 h in the racecadotril
group, although this was not signiﬁcant (MD −2.59 stools per
day, 95% CI −5.26 to 0.08, ﬁgure 4). There was signiﬁcant het-
erogeneity, with the result showing a signiﬁcantly signiﬁcant dif-
ference favouring racecadotril when using the ﬁxed-effects
model (MD −2.57 stools per day, 95% CI −3.03 to −2.30).
Further subgroup analyses were planned but could not be per-
formed due to limited data within the included studies.
Safety
Meta-analysis of ﬁve studies with 949 participants showed no
signiﬁcant difference in reported adverse events between raceca-
dotril and placebo (OR 0.99, 95% CI 0.73 to 1.34, ﬁgure 5).
Studies totalled events, but did not give a speciﬁc breakdown of
speciﬁc events. Events reported included vomiting, abdominal
distension, abdominal pain, rashes and one case of transient
raised transaminases (racecadotril).
No serious adverse events were reported in any study. Funnel
plots of these analyses were symmetrical.
Racecadotril versus loperamide
As there was only one study, no meta-analysis was performed.
Efﬁcacy
The duration of diarrhoeal symptoms was reported as similar
between the two groups (mean (SE) 10.7 (1.7) h with racecado-
tril vs 8.8 (2.3) h with loperamide).
Safety
The incidence of adverse events was lower with racecadotril
than with loperamide and signiﬁcantly more patients on lopera-
mide had constipation.
Racecadotril versus kaolin/pectin
As there was only one study, no meta-analysis was performed.
Efﬁcacy
The number of diarrhoeal episodes was reported as signiﬁcantly
less in the racecadotril group (mean total of 18.96 episodes
with kaolin/pectin vs 8.88 with racecadotril).
Safety
Adverse events data were not presented.
Figure 4 Forest plot of stool output per day at 48 h, racecadotril versus placebo.
Figure 5 Forest plot of total reported adverse events, racecadotril versus placebo.
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DISCUSSION
With the new licence for racecadotril in the UK allowing use in
children under 4 years of age, it is important to clearly establish
the evidence base regarding its efﬁcacy and safety. The evidence
synthesised suggests that the addition of racecadotril to ORS
can reduce the duration of symptoms as well as the number and
volume of stools passed during the illness. When these results
are considered in a clinical context they do appear signiﬁcant,
with a reduction of symptoms of >2 days and 130 mL/kg of
stool loss per day likely to have a signiﬁcant impact for both the
child and parent. Adverse events in children receiving racecado-
tril were not statistically signiﬁcantly different from placebo,
suggesting appropriate safety. Heterogeneity in reporting did
not allow any other outcomes to be analysed.
It must be noted that the quality of the evidence base was
less than optimum, with several studies having signiﬁcant
areas where risk of bias was of concern. Clinical heterogen-
eity in terms of the context and countries of studies, as well
as methodological heterogeneity in the outcomes measured,
age of participants and time and setting of recruitment,
further weaken the evidence base, so it is suggested that these
are considered when judging the strength of the ﬁndings.
Additionally, it is worth noting that there have been no
studies completed in the UK.
In examining the introduction of a new treatment such as this
within the UK, there is more to consider than simply efﬁcacy
and safety. Clarifying the evidence base allows those considering
the use of this agent to begin to evaluate these other aspects. A
recent study has sought to complete a UK-centred cost analysis
which suggests that racecadotril is less costly than ORS alone
for the treatment of children with acute diarrhoea.21 However,
such analysis does not consider the context-speciﬁc issues that
will be key to consider when making local decisions about the
introduction of such an agent, including the time of use within
a diarrhoeal illness and whether initiation takes place in primary
or secondary care. Additionally, there are no studies that con-
sider qualitative outcomes that may be key in deciding whether
to employ such an adjunct agent. Considering how the use of
racecadotril changes the impact of such illness on patients,
parents and families would further inform commissioning
bodies and wider stakeholders in the role of this agent.
CONCLUSIONS
There is evidence from this review that racecadotril is more
effective than placebo or no intervention in reducing the dur-
ation of illness and stool output in children with acute diarrhoea
and appears to be safe. The overall quality of the evidence and
strength of these conclusions is limited due to sparse data, het-
erogeneity and risk of bias in the studies. Further work is sug-
gested to consider the qualitative impact on patients and
families within the UK of the use of such an agent as an adjunct
therapy for acute diarrhoeal illness.
Contributors MG conceived the study and led the study and writing of the
manuscript. AA contributed and reviewed the protocol and writing of the manuscript
and ﬁnalised the ﬁnal draft, as well as co-searching and extracting the data.
Competing interests MG has received travel and educational grants from various
companies including Danone, Abbott, Warner Chilcott, Casen Fleet, Norgine, Ferring
and Vifor. These companies had no involvement in the carrying out or reporting of
this or any other research works. Abbott gave a travel grant to present these results
at DDW in 2014 in USA but had no involvement in the planning, execution or
writing of this or any studies. AA has nothing to declare.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement For the study protocol and any further data, please
email morris@betterprescribing.com.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Sands R, Shanmugavadivel D, Stephenson T, et al. Medical problems presenting
to paediatric emergency departments: 10 years on. Emerg Med J 2012;29:
379–82.
2 Gill PJ, Goldacre MJ, Mant D, et al. Increase in emergency admissions to hospital
for children aged under 15 in England, 1999–2010: national database analysis.
Arch Dis Child 2013;98:328–34.
3 Nataro JP. Diarrhea among children in developing countries. Adv Exp Med Biol
2013;764:73–80.
4 Bruzzese E, Lo Vecchio A, Guarino A. Hospital management of children with acute
gastroenteritis. Curr Opin Gastroenterol 2013;29:23–30.
5 Freedman SB, Sivabalasundaram V, Bohn V, et al. The treatment of pediatric
gastroenteritis: a comparative analysis of pediatric emergency physicians’ practice
patterns. Acad Emerg Med 2011;18:38–45.
6 Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination
with antibiotics on treatment outcomes in traveler’s diarrhea: a systematic review
and meta-analysis. Clin Infect Dis 2008;47:1007–14.
7 Eberlin M, Mück T, Michel MC. A comprehensive review of the pharmacodynamics,
pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor
racecadotril. Front Pharmacol 2012;3:93.
8 Szajewska H, Ruszczyński M, Chmielewska A, et al. Systematic review: racecadotril
in the treatment of acute diarrhoea in children. Aliment Pharmacol Ther
2007;26:807–13.
9 Lehert P, Chéron G, Calatayud GA, et al. Racecadotril for childhood gastroenteritis:
an individual patient data meta-analysis. Dig Liver Dis 2011;43:707–13.
10 Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published
research articles. JAMA 1999;281:1110–1.
11 Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies.
In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 (updated March 2011). Chapter 8. The Cochrane
Collaboration, 2011. http://http://www.cochrane–handbook.org
12 Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in
meta-analyses. BMJ 2003;327(7414):557–60.
13 Alam NH, Ashraf H, Khan WA, et al. Efﬁcacy and tolerability of racecadotril in the
treatment of cholera in adults: a double blind, randomised, controlled clinical trial.
Gut 2003;52:1419–23.
14 Alvarez Calatayud G, Pinel G, et al. Efectividad de racecadotrilo en el tratamiento
de la gastroenteritis aguda. Acta Pediatr Esp 2009;67:177–22. http://static.
vademecum.es/documentos/evidencia/tiorfan/AlvarezCalatayud.AnPediatr.pdf
15 Cojocaru B, Bocquet N, Timsit S, et al. Effet du racécadotril sur le recours aux soins
dans le traitement des diarrhées aiguës du nourrisson et de l’enfant. Arch Pédiatr
2002;8:774–9.
16 Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in
children in developed and developing areas: from evidence base to clinical practice.
Expert Opin Pharmacother 2012;13:17–26.
17 Huighebaert S, Awouters F, Tytgat GNJ. Racecadotril versus loperamide:
antidiarrheal research revisited. Dig Dis Sci 2003;48:239–50.
18 Mehta S, Khandelwal PD, Jain VK, et al. A comparative study of racecadotril and
single dose octreotide as an anti-secretory agent in acute infective diarrhoea.
J Assoc Physicians India 2012;60:12–15.
19 Pieścik-Lech M, Shamir R, Guarino A, et al. Review article: the management of
acute gastroenteritis in children. Aliment Pharmacol Ther 2013;37:289–303.
20 Rao SG. Racecadotril (acetorphan) in the treatment of acute watery diarrhoea in
children. J Indian Med Assoc 2002;100:530.
21 Rautenberg TA, Zerwes U, Foerster D, et al. Evaluating the cost utility of
racecadotril for the treatment of acute watery diarrhea in children: the RAWD
model. Clinicoecon Outcomes Res 2012;4:109–16.
22 Tebruegge M. Racecadotril did not improve diarrhoeal symptoms in children
with moderate acute gastroenteritis. Arch Dis Child Educ Pract Ed
2010;95:197.
23 Tormo R, Polanco I, Salazar-Lindo E, et al. Acute infectious diarrhoea in children:
new insights in antisecretory treatment with racecadotril. Acta Paediatr
2008;97:1008–15.
24 Savitha MR. Racecadotrial—a novel drug for treatment of acute watery diarrhoea in
Indian children. Karnataka Pedicon 2005—Conference Abstracts. Pediatric Oncall
[serial online]; 2006 (cited 1 January 2006):3. http://www.pediatriconcall.com/
fordoctor/Conferenceabstracts/racecadotrial.asp
25 Cézard JP, Duhamel JF, Meyer M, et al. Efﬁcacy and tolerability of racecadotril in
acute diarrhea in children. Gastroenterology 2001;120:799–805.
Gordon M, Akobeng A. Arch Dis Child 2016;101:234–240. doi:10.1136/archdischild-2015-309676 239
Original article
group.bmj.com on March 18, 2016 - Published by http://adc.bmj.com/Downloaded from 
26 Gutierrez Castrellon P, Polanco Allue I, Salazar Lindo E. An evidence based
Iberic-Latin American guideline for acute gastroenteritis management in infants and
prescholars (Manejo de la gastroenteritis aguda en menores de 5 anos: un enfoque
basado en la evidencia. Guia de practica clinical Ibero-Latinoamericana. An Pediatr
(Barcelona) 2010;71:e1–220.e20.
27 Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, et al. Racecadotril in the
treatment of acute watery diarrhoea in children. N Engl J Med 2000;343:463–7.
28 Santos M, Marañón R, Miguez C, et al. Use of racecadotril as outpatient treatment
for acute gastroenteritis: a prospective, randomised, parallel study. J Pediatr
2009;155:62–7.
29 Melendez Garcia JM, Rodriguez JT. Racecadotril en el tratamiento de la diarrea
aguda en ninos. Revista de la Facultad de Medicina (Guatemala) 2007;4:25–8.
30 Turck D, Berard H, Fretault N, et al. Comparison of racecadotril and loperamide in
children with acute diarrhoea. Aliment Pharmacol Ther 1999;13:27–32.
240 Gordon M, Akobeng A. Arch Dis Child 2016;101:234–240. doi:10.1136/archdischild-2015-309676
Original article
group.bmj.com on March 18, 2016 - Published by http://adc.bmj.com/Downloaded from 
systematic review and meta-analyses
Racecadotril for acute diarrhoea in children:
Morris Gordon and Anthony Akobeng
doi: 10.1136/archdischild-2015-309676
29, 2015
2016 101: 234-240 originally published online DecemberArch Dis Child 
 http://adc.bmj.com/content/101/3/234
Updated information and services can be found at: 
These include:
Material
Supplementary
 76.DC1.html
http://adc.bmj.com/content/suppl/2015/12/25/archdischild-2015-3096
Supplementary material can be found at: 
References
 #BIBLhttp://adc.bmj.com/content/101/3/234
This article cites 28 articles, 6 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (3853)Child health
 (181)Diarrhoea
 (166)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 18, 2016 - Published by http://adc.bmj.com/Downloaded from 
